# Aires Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aires-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.airespharma.com
- Total disclosed funding: $34M
- Latest round: Series C (Apr 17, 2013)
- Investors on record: 2

## About

Aires Pharmaceuticals Inc. is a digital asset provider specializing in premium domain names, particularly focused on enhancing online presence for businesses in the pharmaceutical and healthcare sectors.Founded in 2006, Aires Pharmaceuticals Inc. is based in San Diego, US. The company primarily operates in the domain name market, offering a unique asset to pharmaceutical companies and healthcare providers. In February 2014, Aires Pharmaceuticals was acquired by Mast Therapeutics, Inc., although the financial details of the transaction were not disclosed. The founder has an extensive background in the industry, having previously established other ventures. The company has successfully managed a Series C funding round in which it raised USD 8.00 mn, bringing the total amount raised to USD 8.00 mn and its current valuation to USD 25.651 mn.Airespharma.com provides a premium domain name valued for its short, memorable, and easily pronounceable format, which is essential for enhancing visibility in a crowded digital marketplace. This digital asset assists clients in improving web traffic and customer engagement, minimizing miscommunication through a unique web address. Target customers include pharmaceutical companies and healthcare providers across North America, Europe, and Asia, enabling them to establish a strong digital presence and facilitate better customer outreach.Airespharma.com generates revenue through the sale and leasing of its domain name. Businesses can either purchase the domain outright for USD 495 or engage in a leasing agreement with monthly payments. This model attracts a diverse clientele, from startups to established companies, looking to secure a prominent online identity in the pharmaceutical sector and related fields.Aires Pharmaceuticals Inc. is focused on expanding its market reach by further promoting its domain offerings to businesses in emerging markets in Asia and Europe by the end of 2024. The funding raised in the Series C round will be utilized to enhance marketing efforts and develop additional digital assets tailored for niche markets within the pharmaceutical industry. Following its acquisition by Mast Therapeutics, the company is expected to align its future growth strategies with the broader goals set by its parent organization.

## Funding rounds

- Series C, Apr 17, 2013, $8M — MPM BioImpact
- Series B, Nov 11, 2010, $20M — ProQuest Investments, MPM BioImpact
- Seed, Sep 24, 2007, $3M — ProQuest Investments
- Series A, Sep 24, 2007, $3M — ProQuest Investments

## Investors

- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Seed, Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C